HMGN (Hemagen Diagnostics) Cyclically Adjusted FCF per Share: $0.00 (As of Sep. 2012)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Hemagen Diagnostics Cyclically Adjusted FCF per Share?

Hemagen Diagnostics HMGN Cyclically Adjusted FCF per Share is $0.00 as of Sep. 2012.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Hemagen Diagnostics's adjusted free cash flow per share for the three months ended in Sep. 2012 was $-0.004. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.00 for the trailing ten years ended in Sep. 2012.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-09-02), Hemagen Diagnostics's current stock price is $0.0002. Hemagen Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2012 was $0.00. Hemagen Diagnostics's Cyclically Adjusted Price-to-FCF of today is .


Hemagen Diagnostics  (OTCPK:HMGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Hemagen Diagnostics Cyclically Adjusted FCF per Share Related Terms


Hemagen Diagnostics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Hemagen Diagnostics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemagen Diagnostics Cyclically Adjusted FCF per Share Chart

Hemagen Diagnostics Annual Data
Trend Sep03 Sep04 Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hemagen Diagnostics Quarterly Data
Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

HMGN vs OBMP, NSPX, ATRX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Hemagen Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hemagen Diagnostics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemagen Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hemagen Diagnostics's Cyclically Adjusted Price-to-FCF falls into.



Hemagen Diagnostics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hemagen Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2012 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2012 (Change)*Current CPI (Sep. 2012)
=-0.004/231.4070*231.4070
=-0.004

Current CPI (Sep. 2012) = 231.4070.

Hemagen Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200212 0.009 180.900 0.012
200303 0.005 184.200 0.006
200306 0.020 183.700 0.025
200309 0.012 185.200 0.015
200312 0.000 184.300 0.000
200403 0.001 187.400 0.001
200406 -0.023 189.700 -0.028
200409 0.002 189.900 0.002
200412 -0.014 190.300 -0.017
200503 -0.005 193.300 -0.006
200506 -0.072 194.500 -0.086
200509 0.004 198.800 0.005
200512 0.005 196.800 0.006
200603 -0.009 199.800 -0.010
200606 0.000 202.900 0.000
200609 -0.043 202.900 -0.049
200612 -0.004 201.800 -0.005
200703 -0.014 205.352 -0.016
200706 -0.005 208.352 -0.006
200709 -0.016 208.490 -0.018
200712 0.003 210.036 0.003
200803 -0.004 213.528 -0.004
200806 -0.022 218.815 -0.023
200809 0.017 218.783 0.018
200812 0.003 210.228 0.003
200903 -0.005 212.709 -0.005
200906 -0.005 215.693 -0.005
200909 0.001 215.969 0.001
200912 -0.009 215.949 -0.010
201003 0.001 217.631 0.001
201006 0.002 217.965 0.002
201009 -0.010 218.439 -0.011
201012 0.002 219.179 0.002
201103 -0.008 223.467 -0.008
201106 -0.022 225.722 -0.023
201109 0.003 226.889 0.003
201112 -0.018 225.672 -0.018
201203 -0.008 229.392 -0.008
201206 0.000 229.478 0.000
201209 -0.004 231.407 -0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $0.00 mean?
Hemagen Diagnostics (HMGN) has a Cyclically Adjusted FCF per Share of $0.00 as of Sep. 2012. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Hemagen Diagnostics and its competitors.
Is Hemagen Diagnostics' Cyclically Adjusted FCF per Share too high?
Hemagen Diagnostics' current Cyclically Adjusted FCF per Share is $0.00.
How does Hemagen Diagnostics' Cyclically Adjusted FCF per Share compare to OBMP and NSPX?
Hemagen Diagnostics' Cyclically Adjusted FCF per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Hemagen Diagnostics and its competitors. Hemagen Diagnostics's current Cyclically Adjusted FCF per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemagen Diagnostics stock overvalued right now?
Hemagen Diagnostics (HMGN) has a current Cyclically Adjusted FCF per Share of $0.00. The current Cyclically Adjusted FCF per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Hemagen Diagnostics (HMGN), the current Cyclically Adjusted FCF per Share is $0.00 as of Sep. 2012. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hemagen Diagnostics Business Description

Address 9033 Red Branch Road, Columbia, MD, USA, 21045
Hemagen Diagnostics Inc is a biotechnology company. It develops, manufactures and markets Food and Drug Administration cleared proprietary medical diagnostic test kits and components. The company's Virgo line of Immunoassays are used to aid in the diagnosis of autoimmune and infectious diseases and acute-phase proteins. The assays utilize multiple technologies including ELISA, immunofluorescence (IFA) and hemagglutination (HA). Its products include ANA Screen ELISA 96 Test System, Rubella IgG ELISA 96 Test System, AMA IFA 48 Test System and others.